Cargando…
Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)
BACKGROUND: Effective antiretroviral therapy reduces HIV-1 RNA levels, improves CD4 T-cell counts, and lowers the risk of opportunistic infections and malignancies. Interleukin-2 (IL-2) has been shown to increase CD4 T-cell numbers mainly by expanding CD4 cells and by prolonging their half-lives. HI...
Autores principales: | Bosch, Ronald J, Pollard, Richard B, Landay, Alan, Aga, Evgenia, Fox, Lawrence, Mitsuyasu, Ronald |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924251/ https://www.ncbi.nlm.nih.gov/pubmed/20687947 http://dx.doi.org/10.1186/1742-6405-7-30 |
Ejemplares similares
-
Nucleotide- and Protein-Dependent Functions of Actg1
por: Sundby, Lauren J., et al.
Publicado: (2022) -
Expanding the genotypic spectrum of ACTG2-related visceral myopathy
por: James, Kiely N., et al.
Publicado: (2021) -
Autosomal Recessive ACTG2-Related Visceral Myopathy in Brothers
por: Mori, Mari, et al.
Publicado: (2022) -
ACTG1 and TLR3 are biomarkers for alcohol-associated hepatocellular carcinoma
por: Gao, Bing, et al.
Publicado: (2019) -
RRAD suppresses the Warburg effect by downregulating ACTG1 in hepatocellular carcinoma
por: Yan, Yingcai, et al.
Publicado: (2019)